Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports
{{output}}
Background: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated substantial clinical activity in metastatic HER2-positive breast cancer. Although ... ...
